Shortened IV Antibiotic Course for Uncomplicated, Late-Onset Group B Streptococcal Bacteremia

Eric R Coon1,2, Raj Srivastava3,2,4, Greg Stoddard2,5

  • 1Division of Inpatient Medicine, eric.coon@hsc.utah.edu.

Pediatrics
|October 13, 2018
PubMed

Insights

Shortened intravenous antibiotic courses for infant group B Streptococcus bacteremia are common and show low recurrence rates. This suggests current guidelines may be longer than necessary for uncomplicated cases.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Neonatology

Background:

  • Guidelines recommend 10-day intravenous (IV) antibiotic therapy for infants with uncomplicated, late-onset group B Streptococcus (GBS) bacteremia.
  • Variability exists in the duration of IV antibiotic treatment prescribed for GBS bacteremia.

Purpose of the Study:

  • To determine the frequency of shortened IV antibiotic courses for GBS bacteremia in infants.
  • To compare GBS disease recurrence rates between prolonged and shortened IV antibiotic courses.

Main Methods:

  • Multicenter retrospective cohort study of infants (7 days to 4 months) with GBS bacteremia (2000-2015).
  • Exposure: shortened IV antibiotic therapy (≤8 days length of stay without central line).
  • Primary outcome: readmission for GBS bacteremia, meningitis, or osteomyelitis within the first year of life.
  • Analysis: propensity-adjusted, inverse probability-weighted regression models.

Main Results:

  • Of 775 infants, 21% received a shortened IV antibiotic course (≤8 days).
  • Shortened course use varied significantly by hospital (0%-67%).
  • GBS recurrence rates were similar: 1.8% for shortened courses vs. 2.3% for prolonged courses (adjusted risk difference: -0.2%).

Conclusions:

  • Shortened IV antibiotic courses are frequently prescribed for uncomplicated, late-onset GBS bacteremia.
  • Low rates of GBS recurrence and treatment failure were observed with shortened courses.

Related Concept Videos

Antibiotic Selection00:57

Antibiotic Selection

Overview
59.9K
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
1.5K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
815
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
527
Diversity of Archaea IV01:29

Diversity of Archaea IV

Hyperthermophilic archaea are a group of extremophiles thriving at temperatures above 80°C, often in hydrothermal vents and volcanic soils where conditions surpass the boiling point of water. At such temperatures, proteins, membranes, and DNA in most organisms degrade, but hyperthermophiles have evolved remarkable adaptations to maintain stability and function.Unique Cellular FeaturesHyperthermophilic membranes are composed of a monolayer of biphytanyl tetraether lipids, which resist...
455
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
289